CA3028683A1 - Pegylated porcine interferon and methods of use thereof - Google Patents
Pegylated porcine interferon and methods of use thereof Download PDFInfo
- Publication number
- CA3028683A1 CA3028683A1 CA3028683A CA3028683A CA3028683A1 CA 3028683 A1 CA3028683 A1 CA 3028683A1 CA 3028683 A CA3028683 A CA 3028683A CA 3028683 A CA3028683 A CA 3028683A CA 3028683 A1 CA3028683 A1 CA 3028683A1
- Authority
- CA
- Canada
- Prior art keywords
- variant
- alpha
- pinf
- seq
- pig
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662352163P | 2016-06-20 | 2016-06-20 | |
| US62/352,163 | 2016-06-20 | ||
| PCT/US2017/037964 WO2017222940A1 (en) | 2016-06-20 | 2017-06-16 | Pegylated porcine interferon and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3028683A1 true CA3028683A1 (en) | 2017-12-28 |
Family
ID=59258379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3028683A Pending CA3028683A1 (en) | 2016-06-20 | 2017-06-16 | Pegylated porcine interferon and methods of use thereof |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10960080B2 (https=) |
| EP (1) | EP3471755B1 (https=) |
| JP (2) | JP7093311B2 (https=) |
| KR (2) | KR102518451B1 (https=) |
| CN (2) | CN117024562A (https=) |
| AU (2) | AU2017280958A1 (https=) |
| BR (1) | BR112018076437A2 (https=) |
| CA (1) | CA3028683A1 (https=) |
| CL (1) | CL2018003697A1 (https=) |
| DK (1) | DK3471755T3 (https=) |
| EA (1) | EA036509B1 (https=) |
| ES (1) | ES2793773T3 (https=) |
| MX (1) | MX391970B (https=) |
| NZ (1) | NZ749962A (https=) |
| PL (1) | PL3471755T3 (https=) |
| PT (1) | PT3471755T (https=) |
| WO (1) | WO2017222940A1 (https=) |
| ZA (1) | ZA201808352B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20170145025A1 (en) | 2015-11-19 | 2017-05-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2916874T3 (es) | 2015-12-17 | 2022-07-06 | Incyte Corp | Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1 |
| AU2016379372A1 (en) | 2015-12-22 | 2018-08-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| BR112018076534A2 (pt) | 2016-06-20 | 2019-04-02 | Incyte Corporation | compostos heterocíclicos como imunomoduladores |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| AU2017382870B2 (en) | 2016-12-22 | 2022-03-24 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
| EP3558990B1 (en) | 2016-12-22 | 2022-08-10 | Incyte Corporation | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| CR20200520A (es) | 2018-03-30 | 2021-03-09 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| WO2019217821A1 (en) | 2018-05-11 | 2019-11-14 | Incyte Corporation | Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators |
| EP4010342A1 (en) | 2019-08-09 | 2022-06-15 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| CN110343164A (zh) * | 2019-08-22 | 2019-10-18 | 安阳工学院 | 一种高活性7位点突变的猪干扰素α突变体及其制备方法和应用 |
| WO2021067217A1 (en) | 2019-09-30 | 2021-04-08 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
| US11866434B2 (en) | 2020-11-06 | 2024-01-09 | Incyte Corporation | Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
| CN113845599B (zh) * | 2021-11-01 | 2023-09-19 | 长春萤火虫生物科技有限公司 | 一种重组猪干扰素融合蛋白及其应用 |
| WO2024241086A1 (en) | 2023-05-24 | 2024-11-28 | Ambrx, Inc. | Pegylated bovine interferon lambda and methods of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858409B1 (en) * | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
| KR960705579A (ko) * | 1993-11-10 | 1996-11-08 | 에릭에스. 딕커 | 개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates) |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US20050226845A1 (en) * | 2004-03-10 | 2005-10-13 | Chih-Ping Liu | Method of treatment using interferon-tau |
| JP2006213597A (ja) * | 2000-07-19 | 2006-08-17 | Pepgen Corp | インターフェロン−タウを用いるｃ型肝炎ウイルスの処置のための組成物およびモニタリングの方法 |
| EP2327724A3 (en) | 2004-02-02 | 2011-07-27 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
| WO2006133089A2 (en) | 2005-06-03 | 2006-12-14 | Ambrx, Inc. | Improved human interferon molecules and their uses |
| US7695710B2 (en) * | 2005-06-20 | 2010-04-13 | Pepgen Corporation | Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs |
| CN101883784B (zh) | 2007-10-01 | 2014-10-15 | 药华医药股份有限公司 | N-端修饰的干扰素-α |
| PT2318029T (pt) | 2008-07-23 | 2018-01-10 | Ambrx Inc | Polipéptidos de g-csf bovino modificados e suas utilizações |
| CN104262480B (zh) * | 2014-09-28 | 2018-03-27 | 重庆理工大学 | 重组猪长效‑α干扰素的构建和修饰方法及其冻干注射剂的制备方法 |
-
2017
- 2017-06-16 KR KR1020227019809A patent/KR102518451B1/ko active Active
- 2017-06-16 CA CA3028683A patent/CA3028683A1/en active Pending
- 2017-06-16 PT PT177345840T patent/PT3471755T/pt unknown
- 2017-06-16 WO PCT/US2017/037964 patent/WO2017222940A1/en not_active Ceased
- 2017-06-16 JP JP2018566519A patent/JP7093311B2/ja active Active
- 2017-06-16 EA EA201892671A patent/EA036509B1/ru unknown
- 2017-06-16 NZ NZ749962A patent/NZ749962A/en unknown
- 2017-06-16 AU AU2017280958A patent/AU2017280958A1/en not_active Abandoned
- 2017-06-16 KR KR1020187036853A patent/KR102409470B1/ko active Active
- 2017-06-16 DK DK17734584.0T patent/DK3471755T3/da active
- 2017-06-16 CN CN202310995289.4A patent/CN117024562A/zh active Pending
- 2017-06-16 EP EP17734584.0A patent/EP3471755B1/en active Active
- 2017-06-16 PL PL17734584T patent/PL3471755T3/pl unknown
- 2017-06-16 ES ES17734584T patent/ES2793773T3/es active Active
- 2017-06-16 MX MX2018016295A patent/MX391970B/es unknown
- 2017-06-16 BR BR112018076437-0A patent/BR112018076437A2/pt active Search and Examination
- 2017-06-16 CN CN201780051072.0A patent/CN109641034B/zh active Active
- 2017-06-16 US US16/311,540 patent/US10960080B2/en active Active
-
2018
- 2018-12-11 ZA ZA2018/08352A patent/ZA201808352B/en unknown
- 2018-12-19 CL CL2018003697A patent/CL2018003697A1/es unknown
-
2021
- 2021-02-26 US US17/186,642 patent/US20210177980A1/en active Pending
- 2021-09-06 AU AU2021229132A patent/AU2021229132B2/en active Active
-
2022
- 2022-06-17 JP JP2022098147A patent/JP7441892B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3471755A1 (en) | 2019-04-24 |
| DK3471755T3 (da) | 2020-05-18 |
| JP7093311B2 (ja) | 2022-06-29 |
| EA036509B1 (ru) | 2020-11-18 |
| KR20190039889A (ko) | 2019-04-16 |
| KR102409470B1 (ko) | 2022-06-16 |
| ZA201808352B (en) | 2020-08-26 |
| EA201892671A1 (ru) | 2019-05-31 |
| MX2018016295A (es) | 2019-09-16 |
| AU2021229132B2 (en) | 2023-04-06 |
| EP3471755B1 (en) | 2020-04-22 |
| AU2017280958A1 (en) | 2018-12-20 |
| CL2018003697A1 (es) | 2019-05-10 |
| JP2019519553A (ja) | 2019-07-11 |
| US10960080B2 (en) | 2021-03-30 |
| CN109641034B (zh) | 2023-08-15 |
| PT3471755T (pt) | 2020-05-22 |
| CN117024562A (zh) | 2023-11-10 |
| BR112018076437A2 (pt) | 2019-10-01 |
| MX391970B (es) | 2025-03-21 |
| WO2017222940A1 (en) | 2017-12-28 |
| CN109641034A (zh) | 2019-04-16 |
| NZ749962A (en) | 2020-06-26 |
| US20210177980A1 (en) | 2021-06-17 |
| PL3471755T3 (pl) | 2020-10-19 |
| AU2021229132A1 (en) | 2021-09-30 |
| KR20220086700A (ko) | 2022-06-23 |
| KR102518451B1 (ko) | 2023-04-04 |
| JP7441892B2 (ja) | 2024-03-01 |
| ES2793773T3 (es) | 2020-11-16 |
| US20190192673A1 (en) | 2019-06-27 |
| JP2022137063A (ja) | 2022-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021229132B2 (en) | Pegylated Porcine Interferon and Methods of Use Thereof | |
| ES2983610T3 (es) | Hormona del crecimiento de acción prolongada y métodos para producir la misma | |
| ES2494792T3 (es) | Polipéptidos de acción prolongada y métodos para producirlos y administrarlos | |
| KR20090089316A (ko) | Ｐｅｇ 변형된 엑센딘 또는 엑센딘 유사체 및 조성물 및 이의 용도 | |
| US11530249B2 (en) | Long-acting conjugates of GLP-2 derivatives | |
| US12226487B2 (en) | Therapeutic derivatives of interleukin-22 | |
| EA019968B1 (ru) | Модифицированные бычьи полипептиды g-csf и их применение | |
| JP2023540486A (ja) | 免疫原性コロナウイルス融合タンパク質および関連方法 | |
| KR20240052851A (ko) | 항바이러스성의 구조적으로 스테이플링된 SARS-CoV-2 펩티드-콜레스테롤 접합체 및 이의 용도 | |
| CN101671390B (zh) | 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途 | |
| WO2005105151A1 (en) | Pegylated thymosin 1 derivatives | |
| US10913780B2 (en) | Conjugates, their compositions, their uses, and their methods of making | |
| KR20250028290A (ko) | 선택적 il-23 수용체 길항제로서의 새로운 펩티드 | |
| US20240052330A1 (en) | Blockade of sars-cov-2 infection using hydrocarbon stapled peptides | |
| CN111788220A (zh) | 体内持续释放重组凝血因子ⅷ及其制备方法 | |
| CN101385858B (zh) | 纯化的peg化人生长激素缀合物及其药物制剂 | |
| WO2024241086A1 (en) | Pegylated bovine interferon lambda and methods of use thereof | |
| HK40108760A (zh) | 白细胞介素-22的治疗性衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220616 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250317 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250526 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250526 |